Onco Actu du 30 août 2016

	2.8 Etiologie - Contraceptifs, THS
Rethinking the Use of Hormones to Ease Menopause Symptoms [NY Times] According to Dr. JoAnn E. Manson, an endocrinologist and one of the principal investigators for the W.H.I., “The W.H.I. findings have been seriously misunderstood and misinterpreted,” and millions of women for whom the benefits clearly outweigh the risks are needlessly being denied treatment. “The pendulum has swung too far,” she said.
	3.1 Tabac
The failed history of tobacco harm reduction [The Conversation] E-cigarettes are the latest kids on the tobacco harm-reduction block, although their users insist they are not tobacco, smoking or cigarettes. Like all their predecessors, their promoters have graduated from hype school.
	4. Dépistage, diagnostic et pronostic
When a Medical Test Leads to Another, and Another [Wall Street Journal] He says radiologists also “feel trapped legally” by the fear of malpractice suits. “They are only punished for under-diagnosing, not over-diagnosing, so they throw it back to the clinician,” says Dr. Welch.
	5.12 Immunothérapies
EXCLUSIVE: Stealthy Arcus emerges with $120M to make personalized I/O therapy a reality [FierceBiotech] Beyond the general immuno-oncology frothiness, which Rosen expects will result in a lot of disappointing data in the next year or so because of poorly planned combination trials, Rosen and his team are committed to the big vision behind immuno-oncology.
	5.2.3 Pharma - économie
Cancer upstart CBT closes $9.7M Series A; OrbiMed lead investor [FierceBiotech] The company is currently working on a pipeline of four candidates, with its two leading compounds being CBT-101 and CBT-501. The former is an oral c-Met inhibitor designed to target the epithelial to mesenchymal transition (EMT) pathway in certain cancers, while the latter is a PD-1 checkpoint inhibitor, which works by helping the body’s immune system recognize and help kill tumors.
Innovators vs Exploiters: Drug Pricing And The Future Of Pharma [Life Sci VC] The public dialogue on these topics is clearly gaining steam – it will likely come to a froth over the coming months. In this election season, this issue risks becoming an irrational and uninformed political hot potato if Innovators don’t step up and lead.
	5.4 Traitements - Economie
Latest NICE Medtech Innovation Briefings and Technology Appraisal Guidance Recommendations for Cancer [ESMO] In August 2016, NICE issued two medtech innovation briefings on Axxent electronic brachytherapy system for early stage breast cancer and OSNA for colon cancer staging, as well as several technology appraisal guidance documents.
	6. Lutte contre les cancers
Examining Access to Nutrition Care in Outpatient Cancer Centers: Proceedings of a Workshop (2016) [NAP] Participants explored how health outcomes and survival of cancer patients in outpatient cancer centers are affected by current standards for nutritional services, nutritional interventions, and benefits associated with oncology patient access to medical nutrition therapy. They also studied the cost of outpatient nutritional care and assessed cost–benefit relationships between oncology nutrition services and health outcomes and survival.
Loose the Hounds [Proto-MGH] Prized for more than 10,000 years as loyal companions, domestic dogs now also become a powerful ally in the fight against cancer.
	6.5 Médecines alternatives
To help cancer patients, lawmakers pushed access to a controversial doctor [STAT] From 2011 to 2016, 37 members of Congress wrote to the FDA about Burzynski, several of them numerous times, according to documents obtained by STAT under the Freedom of Information Act. Most of the lawmakers asked the agency to grants constituents “compassionate use exemptions” so that they could try his unapproved drugs, or to allow his clinical trials to proceed.
	6.8 Communication
Are Medical Websites, Like WebMD, Healthful? [NY Times] Do they inform patients so they can have better expectations when they see a doctor, or do they do more harm than good?